Cost effectiveness of haemophilia treatment: a cross-national assessment.
(2005) In Blood Coagulation and Fibrinolysis 16(7). p.477-485- Abstract
- The aim of this study was to assess the incremental cost effectiveness of on-demand versus prophylactic haemophilia therapy in Germany, Sweden, the United Kingdom and The Netherlands from the third-party payers' perspective. Using a decision tree model, the cost effectiveness of on-demand versus prophylactic therapy was analysed by extrapolating data from the European Haemophilia Economic Study to a 1-year analytic time horizon. Five hundred and six patients with severe haemophilia A and B, without inhibitors and at least 14 years of age, were enrolled in this study. Patients treated prophylactically had fewer bleeds than patients treated on-demand. With prophylactic treatment, the incremental cost per avoided bleeding ranged from [Euro... (More)
- The aim of this study was to assess the incremental cost effectiveness of on-demand versus prophylactic haemophilia therapy in Germany, Sweden, the United Kingdom and The Netherlands from the third-party payers' perspective. Using a decision tree model, the cost effectiveness of on-demand versus prophylactic therapy was analysed by extrapolating data from the European Haemophilia Economic Study to a 1-year analytic time horizon. Five hundred and six patients with severe haemophilia A and B, without inhibitors and at least 14 years of age, were enrolled in this study. Patients treated prophylactically had fewer bleeds than patients treated on-demand. With prophylactic treatment, the incremental cost per avoided bleeding ranged from [Euro sign]6650 for patients 30 years of age or younger in Germany to [Euro sign]14 140 for patients over 30 years old in Sweden. If quality of life was taken into account, patients receiving prophylactic treatment had higher mean utilities than patients on on-demand therapy. The incremental effectiveness ratios in Germany were [Euro sign]1.2 million per quality-adjusted life year gained for patients 30 years or younger and HIV-positive and [Euro sign]2.2 million for patients 30 years or younger and HIV-negative. In the group aged over 30 years and HIV-positive the on-demand treatment strategy was dominant, whereas in the over 30 years/HIV-negative group the incremental cost-utility ratio was [Euro sign]4.7 million per quality-adjusted life year. Based on our decision analysis, the use of prophylactic treatment was overall more effective than on-demand therapy in young haemophiliacs, but at extremely high cost. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/143553
- author
- Lippert, Barbara ; Berger, Karin ; Berntorp, Erik LU ; Giangrande, Paul ; van den Berg, Marijke ; Schramm, Wolfgang and Siebert, Uwe
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood Coagulation and Fibrinolysis
- volume
- 16
- issue
- 7
- pages
- 477 - 485
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- wos:000232789300004
- pmid:16175006
- scopus:29144528724
- ISSN
- 1473-5733
- language
- English
- LU publication?
- yes
- id
- 92ad9ecb-d615-4845-88bc-6f9fb6c19c11 (old id 143553)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16175006&dopt=Abstract
- date added to LUP
- 2016-04-01 12:11:33
- date last changed
- 2022-01-27 00:04:20
@article{92ad9ecb-d615-4845-88bc-6f9fb6c19c11,
abstract = {{The aim of this study was to assess the incremental cost effectiveness of on-demand versus prophylactic haemophilia therapy in Germany, Sweden, the United Kingdom and The Netherlands from the third-party payers' perspective. Using a decision tree model, the cost effectiveness of on-demand versus prophylactic therapy was analysed by extrapolating data from the European Haemophilia Economic Study to a 1-year analytic time horizon. Five hundred and six patients with severe haemophilia A and B, without inhibitors and at least 14 years of age, were enrolled in this study. Patients treated prophylactically had fewer bleeds than patients treated on-demand. With prophylactic treatment, the incremental cost per avoided bleeding ranged from [Euro sign]6650 for patients 30 years of age or younger in Germany to [Euro sign]14 140 for patients over 30 years old in Sweden. If quality of life was taken into account, patients receiving prophylactic treatment had higher mean utilities than patients on on-demand therapy. The incremental effectiveness ratios in Germany were [Euro sign]1.2 million per quality-adjusted life year gained for patients 30 years or younger and HIV-positive and [Euro sign]2.2 million for patients 30 years or younger and HIV-negative. In the group aged over 30 years and HIV-positive the on-demand treatment strategy was dominant, whereas in the over 30 years/HIV-negative group the incremental cost-utility ratio was [Euro sign]4.7 million per quality-adjusted life year. Based on our decision analysis, the use of prophylactic treatment was overall more effective than on-demand therapy in young haemophiliacs, but at extremely high cost.}},
author = {{Lippert, Barbara and Berger, Karin and Berntorp, Erik and Giangrande, Paul and van den Berg, Marijke and Schramm, Wolfgang and Siebert, Uwe}},
issn = {{1473-5733}},
language = {{eng}},
number = {{7}},
pages = {{477--485}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Blood Coagulation and Fibrinolysis}},
title = {{Cost effectiveness of haemophilia treatment: a cross-national assessment.}},
url = {{http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16175006&dopt=Abstract}},
volume = {{16}},
year = {{2005}},
}